Clinical trial · Interventional
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation
NCT03010579CI-TRIAL-00025360unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| erythropoietin | Drug | — | UNRESOLVED |
| iron supplementation | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- erythropoietin group
- description
- For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
- interventionNames
- Drug: erythropoietin
- type
- ACTIVE_COMPARATOR
- label
- iron supplementation
- description
- If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
- interventionNames
- Drug: iron supplementation
Primary outcomes (1)
- measure
- complete hemoglobin response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * confirmed lymphoma * first autologous hematopoietic stem cell transplantation * hemoglobin level less than 100 g/L on day +15 post-transplant * written informed consent given by patient or his/her guardian if of minor age. Exclusion Criteria: * HIV positive * Known allergy to recombinant human erythropoietin * Uncontrolled infection
References
Publications (0)
Data not yet available
No reference posted for this study.